BusinessActinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical DevelopmentBy Nasdaq OMXApr 18, 2018, 11:30 AM UTC
BusinessActinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLBy Nasdaq OMXMar 13, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Present at 30th Annual ROTH ConferenceBy Nasdaq OMXMar 7, 2018, 12:30 PM UTC
BusinessActinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLBy Nasdaq OMXFeb 12, 2018, 9:15 PM UTC
BusinessActinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on MyeloablationBy Nasdaq OMXFeb 8, 2018, 1:01 PM UTC
BusinessActinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML PatientsBy Nasdaq OMXFeb 6, 2018, 12:30 PM UTC
BusinessActinium Pharmaceuticals to Present at the BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 5, 2018, 9:15 PM UTC
